Robert L Camp

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
    Fabio Parisi
    Department of Cell Biology, New York University Center for Health Informatics and Bioinformatics, New York University School of Medicine and Cancer Institute, NY 10016, USA
    Breast Cancer Res 12:R66. 2010
  2. pmc Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
    Aymen A Elfiky
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, United States of America
    J Transl Med 9:133. 2011
  3. ncbi request reprint X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Robert L Camp
    Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 10:7252-9. 2004
  4. pmc Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
    Yasmine Nadler
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Breast Cancer Res 10:R35. 2008
  5. pmc Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed
    Irvin M Modlin
    Department of Surgery, Yale University School of Medicine, New Haven, CT 06520 8062, USA
    Ann Surg 244:52-60. 2006
  6. ncbi request reprint Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 15:1179-83. 2006
  7. ncbi request reprint Utility of molecular genetic signatures in the delineation of gastric neoplasia
    Mark Kidd
    Department of Surgery, Yale University School of Medicine, New Haven, CT 06520, USA
    Cancer 106:1480-8. 2006
  8. pmc C-Raf is associated with disease progression and cell proliferation in a subset of melanomas
    Lucia B Jilaveanu
    Yale Cancer Center and Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 15:5704-13. 2009
  9. pmc High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer
    Sriparna Ghosh
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 39:1835-43. 2008
  10. pmc Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
    Janice M Mehnert
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 41:375-84. 2010

Research Grants

Detail Information

Publications71

  1. pmc Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
    Fabio Parisi
    Department of Cell Biology, New York University Center for Health Informatics and Bioinformatics, New York University School of Medicine and Cancer Institute, NY 10016, USA
    Breast Cancer Res 12:R66. 2010
    ..We generated prognostic models that incorporate protein-based molecular markers and clinico-pathological variables to improve survival prediction...
  2. pmc Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
    Aymen A Elfiky
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, United States of America
    J Transl Med 9:133. 2011
    ..We characterized expression of p85 and p110α PI3K subunits and mTOR in RCC specimens and assessed pharmacologic co-targeting of these molecules in vitro...
  3. ncbi request reprint X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Robert L Camp
    Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 10:7252-9. 2004
    ....
  4. pmc Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
    Yasmine Nadler
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Breast Cancer Res 10:R35. 2008
    ....
  5. pmc Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed
    Irvin M Modlin
    Department of Surgery, Yale University School of Medicine, New Haven, CT 06520 8062, USA
    Ann Surg 244:52-60. 2006
    ..To use differential gene expression of candidate markers to discriminate benign appendiceal carcinoids (APCs) from malignant and mixed cell APCs...
  6. ncbi request reprint Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 15:1179-83. 2006
    ..Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  7. ncbi request reprint Utility of molecular genetic signatures in the delineation of gastric neoplasia
    Mark Kidd
    Department of Surgery, Yale University School of Medicine, New Haven, CT 06520, USA
    Cancer 106:1480-8. 2006
    ..This strategy provides a molecular basis to define neuroendocrine gastric carcinoids (GCs), neuronal stromal tumors (GISTs), or epithelial cell (gastric adenocarcinomas [GCAs])-derived tumors...
  8. pmc C-Raf is associated with disease progression and cell proliferation in a subset of melanomas
    Lucia B Jilaveanu
    Yale Cancer Center and Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 15:5704-13. 2009
    ..Although the role of B-Raf in melanoma is well established, little is known about C-Raf. We studied effects of C-Raf knockdown in vitro and assessed expression of C-Raf in a large cohort of melanomas and nevi...
  9. pmc High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer
    Sriparna Ghosh
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 39:1835-43. 2008
    ..Further study of the functional significance of this finding is warranted as well as the prognostic value of these biomarkers in other tumor microenvironment-specific compartments (eg, vessels)...
  10. pmc Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
    Janice M Mehnert
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 41:375-84. 2010
    ..Such assessments could assist with evaluation of these molecules as therapeutic targets in melanoma, ultimately facilitating improved selection of patients for treatment...
  11. doi request reprint Phosphatidylinositol-3-kinase as a therapeutic target in melanoma
    Saadia A Aziz
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 15:3029-36. 2009
    ..We assessed expression of PI3K in melanomas and nevi, and studied associations between PI3K pathway members and in vitro response to a PI3K inhibitor, LY294002...
  12. doi request reprint Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome
    Malini Harigopal
    Yale University School of Medicine, New Haven, CT 06510, USA
    Breast Cancer Res Treat 115:77-85. 2009
    ....
  13. ncbi request reprint Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis
    Paul M Weinberger
    Department of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 24:736-47. 2006
    ..Retinoblastoma (Rb) downregulation by HPV E7 results in p16 upregulation. We hypothesized that p16 overexpression in OSCC defines HPV-induced tumors with favorable prognosis...
  14. pmc Melanoma prognostic model using tissue microarrays and genetic algorithms
    Bonnie E Gould Rothberg
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 27:5772-80. 2009
    ..Here, we propose a multimarker molecular prognostic assay that can help triage patients at increased risk of recurrence...
  15. ncbi request reprint beta-Catenin and p53 analyses of a breast carcinoma tissue microarray
    Gina G Chung
    Section of Medical Oncology, Yale Cancer Center, New Haven, Connecticut 06520, USA
    Cancer 100:2084-92. 2004
    ..Recently, it was shown that p53 down-regulated beta-catenin in a complex fashion. The authors examined the expression of beta-catenin, key members of its signaling pathway, and p53 in a large cohort of breast tumors...
  16. ncbi request reprint The role of genetic markers--NAP1L1, MAGE-D2, and MTA1--in defining small-intestinal carcinoid neoplasia
    Mark Kidd
    Department of Surgery, Yale University School of Medicine, 333 Cedar Street, P O Box 208062, New Haven, Connecticut 06520 8062, USA
    Ann Surg Oncol 13:253-62. 2006
    ..We hypothesized that carcinoid malignancy could be defined by using quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) and immunohistochemical approaches that evaluate potential marker genes...
  17. ncbi request reprint Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome
    Aaron J Berger
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 64:8767-72. 2004
    ....
  18. ncbi request reprint Quantitative analysis of estrogen receptor heterogeneity in breast cancer
    Gina G Chung
    Medical Oncology, Yale Cancer Center, New Haven, CT 06520, USA
    Lab Invest 87:662-9. 2007
    ..It is also likely to be dependent on the biomarker analyzed and suggests further studies should be carried out to determine how these findings may affect clinical decision-making processes...
  19. ncbi request reprint Classification of breast cancer using genetic algorithms and tissue microarrays
    Marisa Dolled-Filhart
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Clin Cancer Res 12:6459-68. 2006
    ..It would be ideal if the familiarity and streamlined nature of immunohistochemistry could be combined with the rigorously quantitative and highly specific properties of nucleic acid-based analysis to predict patient outcome...
  20. ncbi request reprint Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1
    Mark Kidd
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
    Cancer 109:2420-31. 2007
    ..Whether this phenomenon is common to small intestinal carcinoid tumors was investigated...
  21. ncbi request reprint Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implicatio
    Christopher B Moeder
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 25:5418-25. 2007
    ..6-mm spot is equivalent to two to three high-power fields, we used TMAs to assess levels of heterogeneity and to determine optimal representation as a function of outcome...
  22. pmc Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma
    Mary M McCarthy
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 12:3856-63. 2006
    ..We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi...
  23. ncbi request reprint High HSP90 expression is associated with decreased survival in breast cancer
    Elah Pick
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Res 67:2932-7. 2007
    ..Prospective studies are needed to confirm the prognostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors...
  24. ncbi request reprint Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis
    Anthony McCabe
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Natl Cancer Inst 97:1808-15. 2005
    ..We investigated whether some of these disparities result from subjective optimization of antibody concentration...
  25. ncbi request reprint Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 11:8637-43. 2005
    ..Here, we sought to determine the prognostic value of EGFR in ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  26. ncbi request reprint Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors
    Idris Tolgay Ocal
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer 97:1841-8. 2003
    ..In this study, the authors attempted to determine the correlation between RTKs on the basis of their ability to stratify a population according to outcome...
  27. doi request reprint Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer
    Yasmine Nadler
    Department of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 14:4455-62. 2008
    ..We therefore assessed expression of Aurora A and B in breast tumors and studied associations with clinical/pathologic variables...
  28. ncbi request reprint Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma
    Kyle A Divito
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 64:8773-7. 2004
    ..These results suggest studies are needed to evaluate the association between quantitative assessment of Bcl-2 expression and response to Bcl-2 targeting therapy toward the goal of improved response rates to these drugs...
  29. pmc Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort
    Jennifer M Giltnane
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Cancer 115:2400-9. 2009
    ..The authors hypothesized that multiplexed quantitative measurement of ErbB receptor family proteins may allow better prediction of outcome...
  30. pmc Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
    Maria T Baquero
    Yale University School of Medicine, Department of Pathology, 310 Cedar St, New Haven, CT 06520, USA
    Breast Cancer Res 13:R85. 2011
    ..The microtubule stabilizer, MAP-tau, has shown conflicting results. We quantitatively assessed MAP-tau expression in two independent breast cancer cohorts to determine prognostic and predictive value of this biomarker...
  31. pmc The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    J Transl Med 5:6. 2007
    ..Targeting XIAP warrants additional investigation as a therapeutic approach for metastatic melanoma...
  32. ncbi request reprint Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 11:8384-90. 2005
    ..However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of p27 in ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  33. pmc Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning
    Ignat Drozdov
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
    Cancer 115:1638-50. 2009
    ....
  34. ncbi request reprint Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer
    Mary M McCarthy
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 11:5188-94. 2005
    ..We sought to determine the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in early-stage breast cancer...
  35. pmc Vascularity of primary and metastatic renal cell carcinoma specimens
    Saadia A Aziz
    Department of the School of Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Transl Med 11:15. 2013
    ..Clinical studies suggest that metastatic sites are more responsive than primary tumors. Our purpose was to characterize microvessel area (MVA) in matched primary and metastatic samples and in samples of different histologies...
  36. doi request reprint Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome
    Rossitza Lazova
    Departments of Dermatology and Pathology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Cancer Res 18:370-9. 2012
    ..Accordingly, we investigated LC3B as an autophagosome marker by analyzing nearly 1,400 tumors from 20 types of cancer, focusing on correlations with clinical outcomes in melanoma and breast cancer...
  37. ncbi request reprint Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis
    Panteleimon Kountourakis
    Yale Cancer Center, PO Box 208032, New Haven, CT 06520, USA
    Thromb Haemost 101:541-6. 2009
    ..341-1.027, p = 0.045). The possibility that KLK8 may be a suitable candidate as a diagnostic and prognostic marker warrants further investigation...
  38. doi request reprint Automated analysis of tissue microarrays
    Marisa Dolled-Filhart
    HistoRx, Inc, New Haven, CT, USA
    Methods Mol Biol 664:151-62. 2010
    ..Ultimately this allows for a multiplexed, objective and standardized quantitative approach for biomarker research and diagnostic assay development for protein expression in tissue...
  39. doi request reprint Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib
    Lucia Jilaveanu
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 15:1076-85. 2009
    ..We assessed the expression of sorafenib targets in SCP-treated patient specimens and evaluated the association with response and progression-free survival...
  40. pmc Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma
    Saadia A Aziz
    Department of Pathology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut 06510, USA
    Clin Cancer Res 16:6029-39. 2010
    ..We studied in vitro activity of a novel dual PI3K/mTOR inhibitor NVP-BEZ235 and activity of the combination of NVP-BEZ235 and the MAP/ERK kinase (MEK) inhibitor AZD6244...
  41. ncbi request reprint Coexpression of beta1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome
    Summar F Siddiqui
    Department of Pathology, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06520 8023, USA
    Cancer Epidemiol Biomarkers Prev 14:2517-23. 2005
    ..Our results indicate that GnT-V substrate proteins represent a unique subset of coexpressed tumor markers associated with aggressive disease...
  42. ncbi request reprint Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis
    Harriet M Kluger
    Departments of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 10:173-7. 2004
    ..Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data...
  43. ncbi request reprint Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome
    Marisa Dolled-Filhart
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 66:5487-94. 2006
    ..These results suggest that loss of beta-catenin expression at the membrane, as assessed by objective quantitative analysis methods, may be useful as a prognostic marker or may be part of a useful algorithm for prognosis in breast cancer...
  44. ncbi request reprint Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma
    Ziwei Yu
    Department of Otolaryngology, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Cancer Res 11:1160-6. 2005
    ..In this study, we sought to determine the prognostic significance of the cell cycle regulator cyclin D1 in oropharyngeal squamous cell carcinoma (OSCC)...
  45. ncbi request reprint Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer
    Malini Harigopal
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 11:4083-9. 2005
    ..We investigated the relationship between E-cadherin expression in primary invasive ductal tumors and corresponding nodal metastases, and determined the prognostic value of E-cadherin expression in node-positive breast cancer...
  46. doi request reprint AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma
    Mark D Gustavson
    Department of Pathology, Yale University, New Haven, CT 06511, USA
    Arch Pathol Lab Med 132:1746-52. 2008
    ..Increased thymidylate synthase expression is a marker for decreased survival in colorectal cancer...
  47. doi request reprint A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers
    Robert L Camp
    Department of Pathology, Yale University School of Medicine, 310 Cedar St, PO Box 208023, New Haven, CT 06520 8023, USA
    J Clin Oncol 26:5630-7. 2008
    ..We will also discuss the role of TMAs in the latest revolution in cancer treatment, the use of targeted drug therapy...
  48. ncbi request reprint Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Res 65:5578-87. 2005
    ....
  49. ncbi request reprint Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome
    Maciej P Zerkowski
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Invest 25:19-26. 2007
    ....
  50. pmc Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease
    Mark Kidd
    Department of Surgery, Yale University School of Medicine, New Haven, CT 06520 8062, USA
    Ann Surg 243:273-80. 2006
    ..Message and protein expression of CgA was examined to evaluate the sensitivity of a PCR-based approach in the detection of covert neuroendocrine (NE) tissue...
  51. ncbi request reprint Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray
    Gina G Chung
    Yale Cancer Center and Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer 106:1677-84. 2006
    ....
  52. ncbi request reprint Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model
    Sharon Pozner-Moulis
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Lab Invest 87:251-60. 2007
    ....
  53. doi request reprint Lymph node ratio should be considered for incorporation into staging for breast cancer
    Anees B Chagpar
    Department of Surgery, Yale University School of Medicine, New Haven, CT, USA
    Ann Surg Oncol 18:3143-8. 2011
    ..We sought to determine whether lymph node ratio (LNR; defined as number of positive nodes/number of nodes dissected) provides additional prognostic information in node-positive breast cancer patients...
  54. ncbi request reprint Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome
    Robert L Camp
    Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 63:1445-8. 2003
    ..Our studies suggest that in situ quantitative measurement of HER2 stratifies breast tumors into three expression levels: normal, intermediate, and high, where both normal and high levels are associated with a worse outcome...
  55. ncbi request reprint Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Melanoma Res 14:207-10. 2004
    ..Our findings suggest that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence...
  56. ncbi request reprint Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome
    Eric Kielhorn
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Int J Cancer 103:652-6. 2003
    ..046). These results suggest that phospho-specific antibodies to beta-catenin define a unique subset of cases and that monitoring of phospho-beta-catenin expression may be useful for assessing prognosis in malignant melanoma...
  57. pmc CD70 expression patterns in renal cell carcinoma
    Lucia B Jilaveanu
    Department of Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 43:1394-9. 2012
    ..Additional studies are warranted to assess the association between expression of CD70 and response to therapy with CD70-targeting drugs in renal cell carcinoma...
  58. pmc In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis
    Veronique Neumeister
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Am J Pathol 176:2131-8. 2010
    ..In this cohort, ALDH1 expression alone does not significantly predict outcome. We conclude that the multiplexed method of in situ identification of putative CSCs identifies high risk patients in breast cancer...
  59. ncbi request reprint Long-term preservation of antigenicity on tissue microarrays
    Kyle A Divito
    Department of Pathology, Yale University, New Haven, CT, USA
    Lab Invest 84:1071-8. 2004
    ..The use of either paraffin coating or nitrogen storage alone protected slides to a lesser degree...
  60. ncbi request reprint Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Lab Invest 88:962-72. 2008
    ..Clustering tumors by VEGF and VEGF-R in tissue components demonstrates distinct tumor phenotypes with different outcomes, and may provide a means for determining which tumors will respond to what antiangiogenic therapies...
  61. pmc Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
    Saadia A Aziz
    Department of Medicine and Yale Cancer Center, 333 Cedar St, WWW213, New Haven, CT, 06520, USA
    BMC Clin Pathol 13:3. 2013
    ..abstract:..
  62. ncbi request reprint Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer
    Jung Y Kang
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 63:1101-5. 2003
    ....
  63. pmc Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables
    Yalai Bai
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    Lab Invest 91:1253-61. 2011
    ..This study suggests that core needle biopsies are more accurate for assessment of tissue biomarkers...
  64. ncbi request reprint Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors
    Mark Kidd
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
    Cancer 103:229-36. 2005
    ..The authors postulated that a similar mechanism occurred during the malignant evolution of small bowel carcinoid tumors...
  65. ncbi request reprint Automated subcellular localization and quantification of protein expression in tissue microarrays
    Robert L Camp
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Nat Med 8:1323-7. 2002
    ....
  66. ncbi request reprint Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis
    Marisa Dolled-Filhart
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 9:594-600. 2003
    ....
  67. pmc Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 164:831-40. 2004
    ..In the future, the AMACR AQUA Z-score may be useful in the automated screening and evaluation of prostate tissue biomarkers...
  68. ncbi request reprint ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer
    Ginesa Garcia-Rostan
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 21:3226-35. 2003
    ..ras oncogenic activation has long been demonstrated in thyroid carcinomas of follicular cell derivation, but no consistent relationship has been shown between mutations and clinicopathologic features...
  69. ncbi request reprint Bimodal population or pathologist artifact?
    David L Rimm
    J Clin Oncol 25:2487-8. 2007
  70. ncbi request reprint RET activation and clinicopathologic features in poorly differentiated thyroid tumors
    Massimo Santoro
    Centro di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:370-9. 2002
    ....
  71. ncbi request reprint Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study
    Wen Xie
    Division of Medical Oncology, Department of Internal Medicine, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Cancer Res 62:497-505. 2002
    ..Finally, analysis of a small cohort of hereditary breast cancers failed to reveal any association between BRCA1 or BRCA2 genotype and alterations in Smad signaling...

Research Grants3

  1. Analysis of Late Recurrence in Breast Cancer
    Robert Camp; Fiscal Year: 2005
    ..The proposed research site, the Department of Pathology, has both the intellectual and physical resources to support Dr. Camp's research, and contains both top quality investigators and "state-of- the-art" core facilities. ..
  2. Qualitative Analysis of Tissue Biomarkers and Pathways
    Robert Camp; Fiscal Year: 2006
    ..Once these techniques are developed, they will provide new linear, quantitative, and highly specific assessments of biomarkers and pathways in tissues that can ultimately be used to advance personalized pharmaco-diagnostics. ..